Kura Oncology and Kyowa Kirin Announce FDA Approval of KOMZIFTI(TM) (ziftomenib), the First and Only Once-Daily Targeted Therapy for Adults with Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia
MindBio Therapeutics Announces Results from Landmark Phase 2B Microdosing in Depression Trail
Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040
NEUPATH HEALTH REPORTS THIRD QUARTER 2025 RESULTS
WELL Health Provides Corporate Update on WELLSTAR Reflecting Organic and Inorganic Growth Wins
Sernova Biotherapeutics Closes First Tranche of a Private Placement of Equity Financing to Support Ongoing Clinical Efforts
Bausch + Lomb to Highlight Company Transformation and Growth Strategy at Investor Day
Medicenna Therapeutics Reports Second Quarter Fiscal 2026 Financial Results and Provides a Corporate Update
HLS Therapeutics Announces Q3 2025 Financial Results
Nurexone receives $3.18-million from warrant exercise
Pharmacorp Rx closes $23-million bought deal offering
Cytophage Announces Closing of First Tranche of Non-Brokered Private Placement
Profound signs Australia, NZ distribution deal
Medexus Announces Fiscal Q2 2026 Results, Driven by Strong Year-To-Date Product-Level Performance of GRAFAPEX (treosulfan) for Injection
Perimeter Medical Imaging AI Announces Strong Third Quarter 2025 Financial Results